Deciphera Pharmaceuticals Inc (DCPH)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Steven L. Hoerter
Employees:
300
500 TOTTEN POND ROAD, WALTHAM, MA 02451
781-209-6400

Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST)

Data derived from most recent annual or quarterly report
Market Cap 1.047 Billion Shares Outstanding75.947 Million Avg 30-day Volume 577.196 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.37
Price to Revenue9.2389 Debt to Equity0.0 EBITDA-181.273 Million
Price to Book Value2.9025 Operating Margin-136.7639 Enterprise Value847.817 Million
Current Ratio5.674 EPS Growth0.557 Quick Ratio5.018
1 Yr BETA 1.1215 52-week High/Low 22.76 / 10.14 Profit Margin-131.3834
Operating Cash Flow Growth32.7532 Altman Z-Score3.7856 Free Cash Flow to Firm -149.858 Million
Earnings Report2023-08-03
View SEC Filings from DCPH instead.

View recent insider trading info

Deciphera Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding DCPH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DCPH

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-12 by WALSH DENNIS LEO
  • 4: filed on 2023-03-23 by HOERTER STEVEN L.
  • 4: filed on 2023-03-01 by BRIGHTSTAR ASSOCIATES LLC
  • 4: filed on 2023-02-17 by PITMAN JAMA
  • 4: filed on 2023-02-17 by MARTIN DANIEL C.
  • 4: filed on 2023-02-17 by KELLY THOMAS PATRICK
  • 4: filed on 2023-02-17 by SHERMAN MATTHEW L
  • 4: filed on 2023-02-17 by FLYNN DANIEL LEE
  • 4: filed on 2023-02-16 by HOERTER STEVEN L.
  • 4: filed on 2023-01-24 by BRIGHTSTAR ASSOCIATES LLC

    • Events (8k)

  • 8-K: filed on 2023-05-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-20:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-18:
    Item 8.01: Other Events
  • 8-K: filed on 2023-01-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-12:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-24:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    11 Thousand total shares from 1 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WALSH DENNIS LEO

    • Director
    		 11,000 2023-05-10 3

    HOERTER STEVEN L. PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-03-21 2

    BRIGHTSTAR ASSOCIATES LLC

    • 10% Owner
    		 22,145,707 2023-02-28 2

    SHERMAN MATTHEW L EVP & CHIEF MEDICAL OFFICER

    • Officer
    		 88,145 2023-02-15 4

    KELLY THOMAS PATRICK CHIEF FINANCIAL OFFICER

    • Officer
    		 58,795 2023-02-15 3

    FLYNN DANIEL LEE CHIEF SCIENTIFIC OFFICER

    • Officer
    		 440,451 2023-02-15 3

    MARTIN DANIEL C. CHIEF COMMERCIAL OFFICER

    • Officer
    		 58,381 2023-02-15 3

    PITMAN JAMA SEE REMARKS

    • Officer
    		 45,050 2023-02-15 3

    ALLEN PATRICIA L

    • Director
    		 3,269 2023-01-17 2

    SQUARER RON

    • Director
    		 3,269 2023-01-17 2

    KELLEY SUSAN L.

    • Director
    		 3,269 2023-01-17 2

    FRIEDMAN FRANKLIN STUART

    • Director
    		 3,269 2023-01-17 2

    BENZ EDWARD J. JR

    • Director
    		 18,500 2022-06-23 1

    MARTIN JOHN RICHARD

    • Director
    		 18,500 2022-06-23 1

    BRISTOL JAMES ARTHUR

    • Director
    		 18,500 2022-06-23 1

    TAYLOR MICHAEL DOUGLAS

    • Director
    		 193,752 2021-05-03 0

    MORL CHRISTOPHER JOHN CHIEF BUSINESS OFFICER

    • Officer
    		 0 2020-01-15 0

    NEW LEAF VENTURE MANAGEMENT III, L.L.C.

    NEW LEAF VENTURES III, L.P.

    NEW LEAF BIOPHARMA OPPORTUNITIES I, L.P.

    NEW LEAF VENTURE ASSOCIATES III, L.P.

    NEW LEAF BPO ASSOCIATES I, L.P.

    • 10% Owner
    		 No longer subject to file 2019-08-15 0

    ROSS MICHAEL JAY

    • Director
    		 0 2019-06-11 0

    RUDDY STEPHEN B. CHIEF TECHNICAL OFFICER

    • Officer
    		 0 2019-01-30 0

    RATCLIFFE LIAM

    • Director
    • 10% Owner
    		 0 2018-05-17 0

    ROSEN OLIVER CHIEF MEDICAL OFFICER

    • Officer
    		 0 2017-10-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    WALSH DENNIS LEO - Director

    		2023-05-12 16:05:10 -0400 2023-05-10 P 11,000 $13.86 a 11,000 direct -3.7975 0.7032 3.9381 5 -3.7975 2

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 22:15:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 21:45:05 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 21:15:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 20:45:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 20:15:05 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 19:45:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 19:15:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 18:45:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 18:15:03 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 17:45:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 17:15:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 16:45:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 16:15:03 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 15:45:03 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 15:15:03 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 14:45:05 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 14:15:04 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 13:45:05 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 13:15:03 UTC 4.82 0.25 2000000
    DECIPHERA PHARMACEUTICALS IN DCPH 2023-05-29 12:45:03 UTC 4.82 0.25 2000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund DCPH -1514.0 shares, $-68145.14 2020-08-31 N-PORT
    FundVantage Trust- Gotham Enhanced Index Plus Fund DCPH -126.0 shares, $-5187.42 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund DCPH -49.0 shares, $-2017.33 2020-03-31 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund DCPH -18.0 shares, $-923.4 2020-09-30 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund DCPH -106.0 shares, $-4364.02 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments